The aim of the present paper was to investigate the effect of Shengjie Tongyu granule on vascular remodeling in atherosclerotic mice and the relevant underlying mechanism. Sixty male ApoE-gene-knockout mice, fed a high-fat diet from 6 weeks of age, were randomized into a Shengjie Tongyu granule group (4.00 g/kg/d), a simvastatin group (9.01 mg/kg/d), and a control group (normal saline: 0.2 mL/d). At the ages of 30 and 40 weeks, we sacrificed the mice for various measurements. The results show that treatment with Shengjie Tongyu granule and simvastatin significantly decreased lumen and plaque areas in the aortic root at 30 and 40 weeks of age, decreased grade II elastic fiber lesions in the ascending aorta at 30 weeks of age, and decreased both grade II and III lesions at 40 weeks of age, compared to controls. The content of superoxide anions, and expression of MOMA-2, plasma ICAM-1, and NFκB p50 in 30- and 40-week-old mice in the Shengjie Tongyu granule and simvastatin groups were also significantly reduced compared to the control group. In conclusion, Shengjie Tongyu granule has a clear inhibitory effect on vascular remodeling and on inflammatory pathways in ApoE-gene-knockout mice.

2010-02-01·Zhonghua nan ke xue = National journal of andrology

[Qianlie Jiedu capsule combined with rufloxacin for chronic prostatitis: a randomized double-blind controlled clinical trial].

Article

作者: Lu, Qi-Ming ; Xu, Jian-Chun ; Fu, Li-Jie ; Chen, Yu-Ping

OBJECTIVEFew double-blind controlled trials have been reported on Chinese patent medicines for the treatment of chronic prostatitis. The purpose of this study was to investigate the therapeutic efficacy of Qianlie Jiedu Capsule for chronic prostatitis (CP) by the randomized double-blind controlled method.METHODSEighty CP patients were equally randomized into an experimental and a control group, the former treated with Qianlie Jiedu Capsule + Rufloxacin, and the latter given placebo + Rufloxacin, both for 4 weeks. All the patients were evaluated by NIH-CPSI and EPS examination before and after the medication.RESULTSAfter 4-week treatment, the total score of NIH-CPSI and the scores of pain, voiding symptoms and quality of life were significantly decreased in both groups compared with the baseline (P < 0.05), so did the leukocyte count in EPS (P < 0.05). And the experimental group showed significant drops in the above scores as compared with the control (P < 0.05), except in the leukocyte count in EPS (P > 0.05).CONCLUSIONQianlie Jiedu Capsule combined with Rufloxacin is highly effective for CP by relieving pain and voiding symptoms,decreasing the leukocyte count in EPS and improving the life quality of the patients.

2009-07-01·Zhonghua nan ke xue = National journal of andrology

[Qianlie Beixi capsule for unliquefiable semen: a clinical study of 180 cases].

Article

作者: Zhou, Yu-Chun ; Xu, Fu-Song ; Zhang, Hua-Jun ; Li, Xiang-Ru ; Jin, Bao-Fang ; Liu, Jian-Guo ; Zhang, Xin-Dong ; Li, Ting-Fu ; Shang, Xue-Jun ; Huang, Yu-Feng

OBJECTIVETo investigate the efficacy and possible action mechanism of Qianlie Beixi Capsule in the treatment of unliquefiable semen.METHODSA total of 240 patients with unliquefiable semen were randomly divided into a treatment group (n = 180), treated with Qianlie Beixi Capsule, and a control group (n = 60), given compound tablets of zinc and protein. The treatment lasted two courses of 45 days each, and the seminal changes were observed and recorded.RESULTSOf the patients in the treatment group, 144 were cured, 12 responded and 24 failed to respond to the medication after the first course; and 158 were cured, 7 responded and 15 failed to after the second course, with the effectiveness rate of 91.67%. Meanwhile, sperm motility was obviously improved, with statistically significant difference from that of the controls (P < 0.01).CONCLUSIONQianlie Beixi Capsule is effective for unliquefiable semen by improving the function of the prostate and shortening the time of seminal liquefaction.

100 项与前列通瘀胶囊相关的药物交易

登录后查看更多信息